8-K: Cyanotech Amends Promissory Note, CEO Employment Agreement Renewed

Cyanotech Corporation amended its promissory note with Skywords Family Foundation, allowing for interest payments in common stock, and renewed the employment agreement with CEO Matthew K. Custer.

Summary

• Cyanotech Corporation entered into a Fourth Amendment to its Amended and Restated Promissory Note with Skywords Family Foundation, Inc. on May 2, 2025.
• The amendment allows Cyanotech, at its discretion, to pay interest accrued during the fiscal year ending March 31, 2026, in the form of its common stock at $1.00 per share.
• Skywords Family Foundation, Inc. is controlled by Michael Davis, Cyanotech's Chairman of the Board and largest stockholder.
• Effective June 16, 2025, Cyanotech renewed the Executive Employment Agreement with Matthew K. Custer as President and CEO for a term ending June 16, 2029, with successive one-year renewals unless terminated.
• Custer's annual base salary is $225,000, with $200,000 in cash and $25,000 in restricted stock units vesting over three years; the salary will increase to $250,000 when the company has two consecutive audited break-even quarters.
• Custer is eligible for a $25,000 signing bonus at the company's discretion when it is in a stronger cash position.
• Custer will receive a one-time grant of stock options to acquire 150,000 shares of Cyanotech's common stock on June 16, 2025, vesting in equal installments over three years, with the exercise price set at the closing market price on the grant date.
• The agreement includes a six-month post-termination non-compete covenant and a five-year post-termination non-disparagement covenant.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The amendment to the promissory note provides financial flexibility, and the renewal of the CEO's contract ensures leadership continuity. However, the reliance on stock for interest payments could be a concern for shareholders.

Positives

• The amendment to the promissory note provides Cyanotech with flexibility in managing its cash flow by allowing for interest payments in common stock.
• Renewal of the CEO's employment agreement provides stability and continuity in leadership.
• The potential signing bonus for the CEO is tied to the company's improved cash position, aligning incentives with financial performance.
• The CEO's salary increase is linked to achieving break-even quarters, incentivizing profitability.

Risks

• The reliance on common stock for interest payments could dilute existing shareholders' equity.
• The company's ability to pay the signing bonus and increase the CEO's salary is contingent on achieving a stronger cash position and break-even quarters, which may not materialize.
• The non-compete and non-disparagement clauses could limit the CEO's future opportunities.

Future Outlook

The company's future performance is tied to achieving break-even quarters to trigger the CEO's salary increase and potentially issue a signing bonus. The ability to pay interest in common stock provides financial flexibility.

Industry Context

In the nutraceuticals industry, managing cash flow and retaining key executives are critical. Allowing interest payments in stock is a strategy sometimes used by companies facing cash constraints. Executive compensation packages are designed to align management incentives with shareholder value.

Comparison to Industry Standards

• Executive compensation packages in the nutraceuticals industry vary widely depending on company size, profitability, and growth stage.
• Base salaries for CEOs of similar-sized companies typically range from $200,000 to $500,000, with additional incentives such as bonuses and stock options.
• Granting stock options is a common practice to align executive interests with shareholder value, similar to companies such as Nutranext and Nature's Bounty.
• The use of restricted stock units and performance-based bonuses is also a standard practice, as seen in companies like Herbalife and USANA Health Sciences.
• The non-compete and non-disparagement clauses are standard in executive employment agreements to protect the company's interests, similar to agreements in place at GNC and Vitamin Shoppe.

Related Party Transactions

• The amendment to the promissory note involves Skywords Family Foundation, Inc., which is controlled by Michael Davis, Cyanotech's Chairman of the Board and largest stockholder.

Stakeholder Impact

• Shareholders may experience dilution if the company elects to pay interest in common stock.
• Employees benefit from the stability of the CEO's continued leadership.
• Creditors are impacted by the potential use of common stock for interest payments.

Next Steps

• The company will issue common stock to Skywords Family Foundation, Inc. for interest payments if it elects to do so for the fiscal year ending March 31, 2026.
• The company will grant stock options to Matthew K. Custer on June 16, 2025.
• The company will monitor its financial performance to determine when it can issue the signing bonus to the CEO and increase his base salary.

Key Dates

Keywords

Cyanotech, promissory note, employment agreement, CEO, Matthew K. Custer, Skywords Family Foundation, stock options, interest payment, common stock, executive compensation